- Home
- SQFT vs VRAX Comparison
SQFT vs VRAX Comparison
Compare SQFT & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- VRAX
- Stock Information
- Founded
- SQFT 1999
- VRAX 2013
- Country
- SQFT United States
- VRAX United Kingdom
- Employees
- SQFT N/A
- VRAX N/A
- Industry
- SQFT Real Estate Investment Trusts
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SQFT Real Estate
- VRAX Health Care
- Exchange
- SQFT Nasdaq
- VRAX Nasdaq
- Market Cap
- SQFT 8.1M
- VRAX 7.3M
- IPO Year
- SQFT 2020
- VRAX 2022
- Fundamental
- Price
- SQFT $0.67
- VRAX $1.87
- Analyst Decision
- SQFT
- VRAX
- Analyst Count
- SQFT 0
- VRAX 0
- Target Price
- SQFT N/A
- VRAX N/A
- AVG Volume (30 Days)
- SQFT 27.0K
- VRAX 304.3K
- Earning Date
- SQFT 03-04-2025
- VRAX 02-05-2025
- Dividend Yield
- SQFT N/A
- VRAX N/A
- EPS Growth
- SQFT N/A
- VRAX N/A
- EPS
- SQFT N/A
- VRAX N/A
- Revenue
- SQFT $18,586,052.00
- VRAX $84,872.00
- Revenue This Year
- SQFT N/A
- VRAX $5,169.18
- Revenue Next Year
- SQFT N/A
- VRAX $66.97
- P/E Ratio
- SQFT N/A
- VRAX N/A
- Revenue Growth
- SQFT 5.44
- VRAX 7.03
- 52 Week Low
- SQFT $0.47
- VRAX $0.60
- 52 Week High
- SQFT $1.39
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- SQFT 49.72
- VRAX 48.66
- Support Level
- SQFT $0.62
- VRAX $1.65
- Resistance Level
- SQFT $0.73
- VRAX $2.10
- Average True Range (ATR)
- SQFT 0.05
- VRAX 0.22
- MACD
- SQFT 0.01
- VRAX 0.01
- Stochastic Oscillator
- SQFT 69.23
- VRAX 42.47
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.